AstraZeneca PLC Reports Record-Breaking FY2022 Q4 Earnings on February 9, 2023

Earnings Overview

On February 9, 2023, ASTRAZENECA PLC ($LSE:AZN) reported earnings results for FY2022 Q4, which ended on December 31, 2022. Total revenue for the fourth quarter came in at USD 901.0 million, a 359.7% increase from the same period in the prior year; however, net income decreased by 6.7% to USD 11207.0 million.

Stock Price

The company’s stock opened at £110.4 and closed at £111.9, representing a 4.1% increase from its prior closing price of £107.5. This significant boost in stock price was attributed to the strong performance of the company in the fourth quarter. AstraZeneca PLC reported strong results across key metrics such as total revenue, net income and earnings per share (EPS). The strong performance of AstraZeneca PLC can be attributed to the success of its core businesses, particularly in the areas of oncology and immunology.

Overall, AstraZeneca PLC’s fourth quarter earnings report for fiscal year 2022 was a record-breaking success for the company. With its stock price experiencing a significant surge and its core businesses experiencing tremendous growth, AstraZeneca PLC is well-positioned to continue its success in the coming quarters. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Astrazeneca Plc. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Astrazeneca Plc. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Astrazeneca Plc. More…

Key Ratios Snapshot

Some of the financial key ratios for Astrazeneca Plc are shown below. More…

Analysis

GoodWhale has performed an analysis of ASTRAZENECA PLC‘s fundamentals, and the results show that ASTRAZENECA PLC is strong in dividend, growth, profitability. The Star Chart analysis classifies ASTRAZENECA PLC as a ‘gorilla’, a type of company that has achieved stable and high revenue or earnings growth due to its strong competitive advantage. ASTRAZENECA PLC has a high health score of 7/10, which is due to its cashflows and debt being able to safely ride out any crisis without the risk of bankruptcy. With such attractive fundamentals, ASTRAZENECA PLC is an attractive investment for any investor who is looking for a reliable dividend payer. Its strong competitive advantage and profitability makes it an attractive choice for those who are looking for a long-term growth story. Its strong financial position also makes it an ideal choice for those who are risk averse. More…

Peers

AstraZeneca PLC is a pharmaceutical company that specializes in the development, manufacture, and marketing of prescription drugs. The company has a diversified product portfolio, which includes medications for cardiovascular, gastrointestinal, and respiratory diseases, as well as cancer. AstraZeneca PLC competes with Sanofi SA, Merck & Co Inc, and Pfizer Inc in the global pharmaceutical market.

– Sanofi SA ($OTCPK:SNYNF)

As of 2022, Sanofi SA has a market cap of 100.1B and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and is one of the world’s largest pharmaceutical companies. Sanofi is a diversified company, focused on human health. It covers seven areas: diabetes solutions, rare diseases, multiple sclerosis, oncology, immunology, vaccines and consumer healthcare.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co Inc is a pharmaceutical company with a market cap of 236.25B as of 2022. The company has a return on equity of 28.84%. The company produces a variety of drugs and vaccines for human and animal health.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a research-based pharmaceutical company with a market cap of 241.95B as of 2022. The company has a return on equity of 24.63%. Pfizer’s main focus is on the discovery, development, and commercialization of innovative therapeutics to treat patients with serious diseases. The company has a portfolio of products in various therapeutic areas, including cardiovascular, inflammation, immunology, oncology, pain, and rare diseases.

Summary

Investors reacted positively to AstraZeneca PLC’s strong fourth quarter of FY2022, as the company reported a 359.7% increase in revenue compared to a year ago. Despite the decrease in net income by 6.7%, investors were encouraged by the strong revenue growth, which was driven by an increase in sales of certain key drugs. AstraZeneca’s stock price rose on the news, signaling the market’s confidence in the company’s potential for long-term growth and profitability. With a product portfolio that is well positioned in the healthcare market, AstraZeneca PLC is an attractive investment opportunity for those looking for long-term growth.